Murepavadin is primarily used as an antibiotic in research settings, specifically targeting Gram-negative bacteria. It is particularly effective against Pseudomonas aeruginosa, a common pathogen responsible for severe infections in hospital settings, including pneumonia in patients on ventilators and infections in individuals with cystic fibrosis. Its mechanism involves disrupting the outer membrane of these bacteria, making it a valuable research tool in combating multidrug-resistant strains. This makes it a promising candidate for studying infections where other antibiotics have failed, offering insights into the growing issue of antibiotic resistance in healthcare. This product is a research-grade chemical intended for laboratory use only and not for human or veterinary therapeutic applications.